Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582568 · ClinicalTrials.gov registry record
EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment
A clinical trial, sponsored by Baylor College of Medicine.
- Terminated
- Registry status
- 1
- Enrollment target
NCT01582568 is a clinical trial that was terminated before completion, run by Baylor College of Medicine. The registered enrollment target is 1 participants.
The verdict
NCT01582568 was terminated before completion, sponsored by Baylor College of Medicine.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess perianal and perirectal fistula healing (complete closure) based on endoscopic ultrasound (EUS) evaluation at 3 months and by PDAI (Pouchitis Disease Activity Index) and Fistula Drainage assessment by 6 months, showing no fistula (new or recurrence) in treatment of Crohn's' disease patient with Certolizumab (Cimzia).
Interventions
- DRUG Certolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2011-06 |
| Est. Completion | 2014-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01582568
The ClinicalTrials.gov registry entry for NCT01582568 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Certolizumab is the first listed.
NCT01582568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01582568 about?
NCT01582568 is a clinical study titled "EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment". The primary objective of this study is to assess perianal and perirectal fistula healing (complete closure) based on endoscopic ultrasound (EUS) evaluation at 3 months and by PDAI (Pouchitis Disease Activity Index) and Fistula Drainage assessment by 6 months, showing no fistula (new or recurrence) i...
What is the current status of trial NCT01582568?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2011-06. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01582568?
The interventions under investigation include: Certolizumab (DRUG).
Who is sponsoring clinical trial NCT01582568?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.